Loading...
USA-first international expansion
MedXline intends to begin in the United States. The roadmap covers 141 planned country entries across the Americas, Europe, Asia, and Oceania. Every published assessment below states what the platform is designed to support, which reviews are required, and what still blocks launch.
Status of every region: Not enabled — assessment required. MedXline is not enabled for production use in this region until regional legal, clinical, security, and data-residency reviews are complete. Nothing on this page is a certification or compliance claim.
Planning inventory
Planning scope only — not current availability, regulatory approval, or production authorization.
35
Includes the United States as the first planned market.
44
Country-by-country assessment and authorization required.
48
Country-by-country assessment and authorization required.
14
Country-by-country assessment and authorization required.
These anchor-market pages are the assessments published today; they are not the full 141-country inventory. Each lists the applicable regime, current platform readiness, required legal, clinical, security, and residency reviews, and exact blockers.
HIPAA Privacy, Security, and Breach Notification Rules; HITECH; state privacy laws; FDA clinical-decision-support framework where applicable.
View readiness detail →
PIPEDA plus provincial health-information law (Ontario PHIPA, Alberta HIA, BC PIPA, Quebec Law 25); Health Canada SaMD guidance where applicable.
View readiness detail →
GDPR (Article 9 health data), ePrivacy, EU MDR/MDCG SaMD qualification where applicable, and the EU AI Act's human-oversight obligations.
View readiness detail →
UAE PDPL, federal health-data law with localization defaults, DHA rules for Dubai, and ADHICS for Abu Dhabi entities.
View readiness detail →
Saudi PDPL under SDAIA supervision with cross-border transfer restrictions; SFDA assessment for clinically positioned software; NPHIES ecosystem expectations.
View readiness detail →
Qatar PDPPL with permit requirements for certain sensitive health-data processing; Ministry of Public Health oversight for health services.
View readiness detail →
Privacy Act 1988 (Australian Privacy Principles), My Health Records Act 2012, and TGA regulation of software as a medical device where clinically positioned.
View readiness detail →
MedXline derives from a production-proven care-access platform architecture: verified audit trails, tenant isolation, consent management, offline-capable patient experiences, and human-supervised AI. The current feature surface serves as the reference implementation while regional deployment profiles are built.
Talk to us about your region, your regulatory context, and your timeline. Deployment requires regional legal and clinical review — we will tell you plainly what is ready and what is not.